Benralizumab is under clinical development by AstraZeneca and currently in Phase III for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). According to GlobalData, Phase III drugs for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Benralizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Benralizumab overview

Benralizumab (Fasenra) is a glyco-engineered monoclonal antibody, acts as an anti asthmatic agent. It is formulated as solution for subcutaneous route of administration. Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Benralizumab (MEDI-563, KHK4563, BIW-8405) is under development for the treatment of  non-cystic fibrosis, severe uncontrolled asthma, severe prednisone dependent eosinophilic asthma, exercise-induced bronchoconstriction,  hypereosinophilic syndrome (HES), eosinophilic chronic rhinosinusitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome), chronic obstructive pulmonary disease (COPD), severe nasal polyposis, bullous pemphigoid and gastroenteritis.

It was also under development for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD),eosinophilic esophagitis, bronchiectasis, eosinophilic gastritis and chronic spontaneous urticaria (Chronic Urticaria Or Hives).

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of Benralizumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.